SenesTech, Inc. (NASDAQ:SNES) Sees Large Decline in Short Interest

SenesTech, Inc. (NASDAQ:SNES) saw a large decline in short interest in December. As of December 31st, there was short interest totalling 34,600 shares, a decline of 64.1% from the December 15th total of 96,500 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Several hedge funds and other institutional investors have recently made changes to their positions in SNES. Bank of New York Mellon Corp grew its stake in shares of SenesTech by 126.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 76,633 shares of the company’s stock valued at $123,000 after buying an additional 42,780 shares in the last quarter. Geode Capital Management LLC bought a new stake in shares of SenesTech in the 2nd quarter valued at approximately $165,000. Renaissance Technologies LLC bought a new stake in shares of SenesTech in the 2nd quarter valued at approximately $321,000. State Street Corp bought a new stake in shares of SenesTech in the 2nd quarter valued at approximately $40,000. Finally, Citadel Advisors LLC grew its stake in shares of SenesTech by 53.2% in the 3rd quarter. Citadel Advisors LLC now owns 20,748 shares of the company’s stock valued at $32,000 after buying an additional 7,205 shares in the last quarter. 4.07% of the stock is owned by institutional investors and hedge funds.

NASDAQ:SNES opened at $0.99 on Friday. SenesTech has a fifty-two week low of $0.93 and a fifty-two week high of $3.14. The stock’s 50-day moving average is $1.17 and its two-hundred day moving average is $1.44. The stock has a market cap of $12.08 million, a PE ratio of -1.15 and a beta of 1.51.

SenesTech (NASDAQ:SNES) last released its earnings results on Wednesday, November 10th. The company reported ($0.18) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.18). SenesTech had a negative return on equity of 67.90% and a negative net margin of 1,490.15%. The company had revenue of $0.18 million for the quarter, compared to analysts’ expectations of $0.22 million. During the same quarter in the previous year, the business posted ($0.56) EPS. Sell-side analysts forecast that SenesTech will post -0.71 EPS for the current year.

About SenesTech

SenesTech, Inc engages in the development and commercialization of a proprietary technology for the management of animal pest populations, primarily rat populations through fertility control. It offers its ContraPest product to residential, and commercial sector such as animal, structural, and food markets.

Featured Article: What is the Moving Average Convergence Divergence (MACD) oscillator?

Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.